One Broadway 14th Floor,
Cambridge, Massachusetts 02142
Gloucester develops cancer therapies including Istodax, which was approved by the Food and Drug Administration last month for treatment of cutaneous T-cell lymphoma patients who have had a least one prior systemic therapy. The treatment also has orphan drug designation for treatment of non-Hodgkin's T-cell lymphomas including CTCL and peripheral T-cell lymphoma, as well as fast-track status for PTCL.
Gloucester Pharmaceuticals was acquired by Celgene on December 07, 2009.
Join Mergr to view all 111 acquisitions of life science companies in 2009, including 13 acquisitions by private equity firms, and 98 by strategics.
Join Mergr to view this profile - and discover more life science acquisitions of companies like Gloucester Pharmaceuticals.
No obligation. Cancel anytime.